Moderna
MRNA
954 hedge funds and large institutions have $31.1B invested in Moderna in 2024 Q2 according to their latest regulatory filings, with 128 funds opening new positions, 333 increasing their positions, 305 reducing their positions, and 64 closing their positions.
100% more first-time investments, than exits
New positions opened: 128 | Existing positions closed: 64
63% more funds holding in top 10
Funds holding in top 10: 8 → 13 (+5)
11% more capital invested
Capital invested by funds: $28.1B → $31.1B (+$3.05B)
6% more funds holding
Funds holding: 902 → 954 (+52)
9% more repeat investments, than reductions
Existing positions increased: 333 | Existing positions reduced: 305
0.39% less ownership
Funds ownership: 68.77% → 68.39% (-0.39%)
16% less call options, than puts
Call options by funds: $1.56B | Put options by funds: $1.86B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$957M |
| 2 |
Jane Street
New York
|
+$104M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$73.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$72.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$637M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$191M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$163M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$153M |
| 5 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$77.8M |
MRNA Hedge Fund Activity: Q2 2024 in Review
954 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q2 2024, worth a combined $31.1B — up 11% from $28.1B a quarter earlier.
Buyers outnumbered sellers: 128 funds opened new MRNA positions and 64 closed out — a net gain of 64 holders — while 333 added to existing stakes and 305 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $957M. The largest seller was Flagship Pioneering, cutting an estimated $637M.
- 954 institutional investors held Moderna (MRNA) as of Q2 2024, up from 902 in Q1 2024.
- Funds reported $31.1B of Moderna stock for Q2 2024, up 11% quarter-over-quarter.
- 128 funds opened new Moderna positions in Q2 2024 and 64 closed out, a net change of +64 holders.
- The largest Moderna buyer in Q2 2024 was Fidelity Investments, an estimated $957M added.
- The largest Moderna seller in Q2 2024 was Flagship Pioneering, an estimated $637M sold.
Based on aggregated 13F filings for Q2 2024.